Revenue fell 37% to 11,047 tkr and net loss widened to -5,147 tkr, but cash remains stable and a 15.2 MSEK rights issue is planned to fund growth. FDA validation and new partnerships support future prospects.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.